Get the Stockscreener App
2.00
5.26%
0.10
After Hours:
2.00
Immuron Limited Adr stock is traded at $2.00, with a volume of 31,078.
It is up +5.26% in the last 24 hours and down -6.98% over the past month.
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.
See More
Previous Close:
$1.90
Open:
$1.9
24h Volume:
31,078
Relative Volume:
0.49
Market Cap:
$13.41M
Revenue:
$2.35M
Net Income/Loss:
$-2.56M
P/E Ratio:
-4.4633
EPS:
-0.4481
Net Cash Flow:
-
1W Performance:
-9.09%
1M Performance:
-6.98%
6M Performance:
+4.17%
1Y Performance:
+2.47%
1-Day Range:
$1.90
$2.00
1-Week Range:
$1.80
$2.2099
52-Week Range:
$1.50
$2.483
Immuron Limited Adr Stock (IMRN) Company Profile
Compare IMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRN
Immuron Limited Adr
|
2.00 | 12.79M | 2.35M | -2.56M | 0 | -0.4481 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.00 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
642.25 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.07 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
826.28 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.23 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Immuron Limited Adr Stock (IMRN) Latest News
[6-K] Immuron Ltd Current Report (Foreign Issuer) - Stock Titan
Immuron Announces Clinical Trial Update - GlobeNewswire Inc.
Immuron Announces Clinical Trial Update - Sahm
Immuron CEO to Present at AusBiotech Invest 2025 Conference - TipRanks
IMRN furnishes 6-K with ASX updates and Exhibit 99.1 - Stock Titan
Immuron Ltd. (ADR) (US45254U1016.SG) Stock Price, News, Quote & History - Yahoo
Immuron Limited Announces 2025 Annual General Meeting - MSN
[6-K] Immuron Ltd Current Report (Foreign Issuer) | IMRN SEC FilingForm 6-K - Stock Titan
Immuron Submits IMM-529 IND to FDA - markets.businessinsider.com
Immuron (IMRN) Seeks FDA Green Light for Novel C. diff Treatment - GuruFocus
Immuron Limited Submits IND Application to FDA for IMM-529 to Combat Clostridioides difficile Infection - Quiver Quantitative
$400M Market Potential: Immuron's C. Difficile Drug IMM-529 Heads to FDA as Company Advances 3 Key Programs - Stock Titan
Immuron Limited Secures Auditor Consent for Financial Filings - MSN
What analysts say about Immuron Limited ANW stockBear Market Strategies & Low Risk Capital Gains - earlytimes.in
Is Immuron Limited Depositary Receipt forming a reversal patternJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
Is it too late to sell Immuron Limited Depositary ReceiptMarket Activity Report & Fast Moving Trade Plans - Newser
Does Immuron Limited Depositary Receipt fit your quant trading modelJuly 2025 Price Swings & High Win Rate Trade Tips - Newser
Statistical indicators supporting Immuron Limited Depositary Receipt’s strengthPortfolio Risk Summary & Real-Time Sentiment Analysis - Newser
What institutional flow reveals about Immuron Limited Depositary ReceiptEarnings Growth Summary & Entry Point Strategy Guides - Newser
Immuron Limited Depositary Receipt stock trend forecastWeekly Investment Summary & AI Optimized Trading Strategy Guides - Newser
Visualizing Immuron Limited Depositary Receipt stock with heatmapsAI Trading Forecast Based on Big Data - Newser
BNY Mellon Increases Stake in Immuron Limited - TipRanks
Immuron Limited Announces Cessation of Securities - TipRanks
What drives Immuron Limited Depositary Receipt stock priceHigh-yield capital appreciation - jammulinksnews.com
Immuron - GlobeNewswire Inc.
Immuron Crushes Sales Forecast: North America Soars 76%, Global Revenue Breaks Records at $7.3M - Stock Titan
immuron ltd files for quotation of securities on ASX By Investing.com - Investing.com South Africa
immuron ltd files for quotation of securities on ASX - Investing.com
IMRNImmuron Ltd Latest Stock News & Market Updates - Stock Titan
Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) - BioSpace
Immuron: Targeted oral antibodies to treat infectious diseases - Innovation News Network
Immuron Travelan® continued strong sales growth - FinancialContent
Immuron: US FDA provides favourable feedback ahead of investigational new drug application for IMM-529 - Proactive financial news
Immuron Plans Phase 2 Trial for IMM-529 following FDA review - GlobeNewswire
Immuron requests pre-IND meeting for IMM-529 with FDA filing - FinancialContent
symbol__ Stock Quote Price and Forecast - CNN
U.S. stocks higher at close of trade; Dow Jones Industrial Average up 0.34% - Investing.com
Immuron Limited Announces Closing of $20.0 Million Registered Direct Offering - Stock Titan
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
IMC Reports Rising Revenues & Eyes Colitis Market - Next Investors
Immuron Limited Issues Correction to Misleading Halt Announcement Headline - GlobeNewswire
IMC Stock Price and Chart — ASX:IMC - TradingView
Immuron Limited (IMRN) stock price, news, quote and history - Yahoo! Finance UK
Immuron Limited Adr Stock (IMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.64%
0.35%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):